cetuximab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
chimeric origin 4954 205923-56-4

Description:

MoleculeDescription

Synonyms:

  • cetuximab
  • cetuximab (genetical recombination)
  • erbitux
  • C-225
  • IMC-C225
A chimeric monoclonal antibody that functions as an ANTINEOPLASTIC AGENT through its binding to the EPIDERMAL GROWTH FACTOR RECEPTOR, where it prevents the binding and signaling action of cell growth and survival factors.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
July 16, 2008 PMDA Merck
Feb. 12, 2004 FDA IMCLONE
June 29, 2004 EMA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dermatitis acneiform 402.33 23.10 107 11477 3950 50589590
Mucosal inflammation 192.92 23.10 118 11466 40024 50553516
Diarrhoea 187.82 23.10 413 11171 588063 50005477
Neutropenia 181.34 23.10 195 11389 147770 50445770
Malignant neoplasm progression 168.27 23.10 133 11451 67991 50525549
Dehydration 157.77 23.10 184 11400 152265 50441275
Hypomagnesaemia 134.57 23.10 77 11507 23079 50570461
Skin toxicity 120.58 23.10 42 11542 3871 50589669
Rash 116.85 23.10 287 11297 437184 50156356
Drug ineffective 100.02 23.10 32 11552 819301 49774239
Paronychia 99.67 23.10 38 11546 4526 50589014
Vomiting 95.27 23.10 275 11309 460483 50133057
Disease progression 92.85 23.10 112 11472 95754 50497786
Infusion related reaction 76.29 23.10 138 11446 169419 50424121
Nausea 73.78 23.10 337 11247 705061 49888479
Pulmonary embolism 73.73 23.10 103 11481 101601 50491939
Radiation skin injury 72.57 23.10 20 11564 843 50592697
Stomatitis 69.56 23.10 100 11484 101244 50492296
Hypokalaemia 66.59 23.10 91 11493 87901 50505639
Serous retinal detachment 63.81 23.10 14 11570 223 50593317
Dermatitis 63.58 23.10 40 11544 14211 50579329
Skin fissures 56.23 23.10 31 11553 8637 50584903
Palmar-plantar erythrodysaesthesia syndrome 55.54 23.10 42 11542 20056 50573484
Arthralgia 55.34 23.10 16 11568 438686 50154854
Metastases to lung 49.33 23.10 31 11553 10989 50582551
Febrile neutropenia 47.08 23.10 82 11502 97585 50495955
Pyrexia 46.63 23.10 191 11393 380012 50213528
Haematotoxicity 42.51 23.10 25 11559 7870 50585670
Thrombocytopenia 40.62 23.10 90 11494 127583 50465957
Deep vein thrombosis 38.55 23.10 64 11520 73240 50520300
Skin reaction 38.37 23.10 27 11557 11541 50581999
Chills 36.36 23.10 73 11511 96614 50496926
Anaemia 35.90 23.10 133 11451 252323 50341217
Decreased appetite 35.67 23.10 114 11470 200809 50392731
Neutrophil count decreased 33.88 23.10 47 11537 45979 50547561
Multiple-drug resistance 33.55 23.10 16 11568 3298 50590242
Weight increased 32.50 23.10 4 11580 201887 50391653
Trichomegaly 32.08 23.10 6 11578 40 50593500
Hypertrichosis 31.73 23.10 11 11573 998 50592542
Rash pustular 30.95 23.10 19 11565 6462 50587078
Ileus 30.82 23.10 25 11559 13204 50580336
Leukopenia 30.33 23.10 55 11529 67473 50526067
Abdominal discomfort 29.98 23.10 8 11576 231633 50361907
Dyspnoea 29.49 23.10 220 11364 547388 50046152
Renal tubular disorder 28.50 23.10 13 11571 2424 50591116
Asthenia 28.40 23.10 146 11438 318896 50274644
Anastomotic leak 27.55 23.10 8 11576 408 50593132
Stress cardiomyopathy 27.54 23.10 19 11565 7868 50585672
Dry skin 27.25 23.10 41 11543 43150 50550390
Drug hypersensitivity 26.75 23.10 12 11572 250998 50342542
Dysphagia 26.17 23.10 56 11528 77462 50516078
Interstitial lung disease 26.06 23.10 45 11539 53131 50540409
Sinusitis 25.98 23.10 4 11580 170554 50422986
Acne 25.97 23.10 27 11557 19568 50573972
Drug intolerance 25.77 23.10 9 11575 219095 50374445
Hypocalcaemia 25.37 23.10 31 11553 26785 50566755
Bone marrow failure 24.63 23.10 31 11553 27593 50565947
Abdominal pain 24.51 23.10 113 11471 236115 50357425
Product dose omission issue 24.45 23.10 6 11578 183832 50409708
Nail disorder 24.01 23.10 19 11565 9689 50583851
Drug interaction 23.82 23.10 8 11576 199613 50393927
Metastases to liver 23.64 23.10 26 11558 20078 50573462
Chemical burns of eye 23.13 23.10 5 11579 74 50593466

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dermatitis acneiform 858.66 19.07 272 23167 5219 29545869
Infusion related reaction 451.42 19.07 331 23108 43555 29507533
Mucosal inflammation 432.17 19.07 284 23155 31311 29519777
Hypomagnesaemia 288.46 19.07 177 23262 17291 29533797
Anaphylactic reaction 276.50 19.07 205 23234 27368 29523720
Rash 267.10 19.07 511 22928 189308 29361780
Dehydration 264.82 19.07 386 23053 114362 29436726
Skin toxicity 264.81 19.07 103 23336 3668 29547420
Radiation skin injury 247.14 19.07 65 23374 615 29550473
Paronychia 219.25 19.07 84 23355 2869 29548219
Stomatitis 186.98 19.07 186 23253 36927 29514161
Malignant neoplasm progression 167.91 19.07 247 23192 73612 29477476
Drug ineffective 139.67 19.07 57 23382 363113 29187975
Neutropenia 124.05 19.07 302 23137 131409 29419679
Dysphagia 119.44 19.07 180 23259 54746 29496342
Chills 108.47 19.07 199 23240 71101 29479987
Acne 102.42 19.07 73 23366 9147 29541941
Hypotension 102.29 19.07 362 23077 193992 29357096
Hypersensitivity 97.85 19.07 161 23278 52742 29498346
Diarrhoea 94.81 19.07 515 22924 332183 29218905
Pharyngeal inflammation 94.17 19.07 26 23413 300 29550788
Palmar-plantar erythrodysaesthesia syndrome 91.44 19.07 83 23356 14676 29536412
Drug interaction 87.82 19.07 24 23415 197361 29353727
Flushing 74.64 19.07 103 23336 28889 29522199
Vomiting 74.62 19.07 349 23090 211911 29339177
Erythema 73.84 19.07 176 23263 75430 29475658
Dermatitis 71.46 19.07 55 23384 7743 29543345
Skin reaction 70.91 19.07 44 23395 4373 29546715
Skin fissures 70.52 19.07 42 23397 3877 29547211
Conjunctivitis 70.23 19.07 55 23384 7943 29543145
Decreased appetite 65.67 19.07 258 23181 145084 29406004
Nausea 63.71 19.07 419 23020 288836 29262252
Rash pustular 63.58 19.07 42 23397 4649 29546439
Arthralgia 62.00 19.07 17 23422 139600 29411488
Radiation mucositis 58.40 19.07 15 23424 128 29550960
Hypocalcaemia 57.10 19.07 76 23363 20589 29530499
Oxygen saturation decreased 53.22 19.07 113 23326 44824 29506264
Pain in extremity 51.80 19.07 12 23427 110421 29440667
Product dose omission issue 50.44 19.07 8 23431 96375 29454713
Pulmonary embolism 49.40 19.07 153 23286 76381 29474707
Fall 49.16 19.07 41 23398 177137 29373951
Pulse absent 48.91 19.07 37 23402 5076 29546012
Device related infection 48.67 19.07 61 23378 15575 29535513
Pyrexia 48.50 19.07 391 23048 287231 29263857
Toxicity to various agents 48.41 19.07 40 23399 173621 29377467
Anaphylactic shock 47.99 19.07 56 23383 13280 29537808
Dyspnoea 47.66 19.07 430 23009 326302 29224786
Disease progression 46.74 19.07 157 23282 81759 29469329
Folliculitis 45.90 19.07 32 23407 3868 29547220
Pruritus 44.54 19.07 197 23242 116652 29434436
Onycholysis 43.70 19.07 16 23423 480 29550608
Condition aggravated 42.90 19.07 32 23407 146263 29404825
Gastrointestinal toxicity 41.40 19.07 24 23415 2107 29548981
Dry skin 40.46 19.07 69 23370 23238 29527850
Ileus 39.83 19.07 53 23386 14349 29536739
Leukopenia 39.03 19.07 114 23325 55089 29495999
Insomnia 39.01 19.07 11 23428 88750 29462338
Proteus infection 38.09 19.07 17 23422 858 29550230
Neutrophil count decreased 37.81 19.07 97 23342 43470 29507618
Neuropathy peripheral 36.91 19.07 132 23307 70895 29480193
Blood magnesium decreased 36.71 19.07 32 23407 5362 29545726
Alopecia 36.48 19.07 59 23380 19025 29532063
Blood pressure immeasurable 35.67 19.07 16 23423 817 29550271
Tumour haemorrhage 35.51 19.07 23 23416 2462 29548626
Interstitial lung disease 35.03 19.07 113 23326 57605 29493483
Gait disturbance 34.32 19.07 8 23431 73341 29477747
Clostridial infection 33.96 19.07 25 23414 3290 29547798
Febrile neutropenia 33.90 19.07 177 23262 112063 29439025
Neoplasm progression 33.49 19.07 56 23383 18556 29532532
Cardio-respiratory arrest 33.40 19.07 102 23337 50499 29500589
Nail dystrophy 32.98 19.07 10 23429 164 29550924
Urticaria 32.26 19.07 106 23333 54554 29496534
Blood pressure decreased 32.22 19.07 94 23345 45383 29505705
Thrombocytopenia 31.78 19.07 199 23240 134624 29416464
Serous retinal detachment 31.36 19.07 12 23427 408 29550680
Nasopharyngitis 31.09 19.07 5 23434 59660 29491428
Weight increased 31.02 19.07 11 23428 76656 29474432
Pneumatosis intestinalis 30.46 19.07 23 23416 3146 29547942
Peripheral swelling 29.72 19.07 7 23432 63732 29487356
Nail disorder 28.85 19.07 18 23421 1806 29549282
Necrotising oesophagitis 28.83 19.07 12 23427 510 29550578
Cardiac failure congestive 27.71 19.07 13 23426 76568 29474520
Myalgia 27.67 19.07 12 23427 74007 29477081
Headache 27.28 19.07 61 23378 173946 29377142
Oesophagitis 27.19 19.07 40 23399 11883 29539205
White blood cell count decreased 26.93 19.07 134 23305 83228 29467860
Laryngeal oedema 26.84 19.07 21 23418 3027 29548061
Prothrombin level decreased 26.26 19.07 14 23425 1044 29550044
Hospitalisation 25.98 19.07 3 23436 45985 29505103
Induration 25.79 19.07 13 23426 863 29550225
Monocytopenia 25.57 19.07 7 23432 78 29551010
Coronary artery disease 24.67 19.07 3 23436 44187 29506901
Anxiety 24.58 19.07 19 23420 85346 29465742
Aspiration 24.44 19.07 35 23404 10145 29540943
Hypophagia 24.13 19.07 52 23387 20820 29530268
Embolism 23.22 19.07 28 23411 6868 29544220
Depression 23.21 19.07 20 23419 85127 29465961
Influenza 23.00 19.07 3 23436 41878 29509210
Anaphylactoid reaction 22.98 19.07 16 23423 1929 29549159
Abdominal discomfort 22.85 19.07 5 23434 47898 29503190
Pneumonitis 22.84 19.07 61 23378 27983 29523105
Hypovolaemic shock 22.68 19.07 26 23413 6046 29545042
Joint swelling 22.08 19.07 6 23433 49624 29501464
Bronchospasm 21.57 19.07 32 23407 9577 29541511
Unresponsive to stimuli 20.82 19.07 55 23384 25071 29526017
Cerebral ischaemia 20.60 19.07 24 23415 5679 29545409
Abdominal compartment syndrome 20.53 19.07 11 23428 828 29550260
Pelvic sepsis 20.52 19.07 4 23435 7 29551081
Metastases to liver 20.44 19.07 35 23404 11821 29539267
Enteritis 20.34 19.07 26 23413 6765 29544323
Metastases to lung 20.34 19.07 28 23411 7827 29543261
Overdose 20.27 19.07 20 23419 79799 29471289
Hypokalaemia 20.12 19.07 86 23353 50117 29500971
Butterfly rash 20.10 19.07 6 23433 93 29550995
Pneumonia aspiration 19.69 19.07 69 23370 36668 29514420
Lymphopenia 19.56 19.07 37 23402 13496 29537592
Muscle spasms 19.35 19.07 14 23425 65068 29486020
Diabetes mellitus 19.32 19.07 4 23435 39827 29511261
Ileal perforation 19.31 19.07 10 23429 702 29550386
Memory impairment 19.12 19.07 3 23436 36467 29514621
Cyanosis 19.08 19.07 33 23406 11234 29539854

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dermatitis acneiform 1117.10 18.70 326 29968 8117 64460321
Mucosal inflammation 443.90 18.70 307 29987 62277 64406161
Hypomagnesaemia 408.67 18.70 241 30053 37135 64431303
Skin toxicity 370.28 18.70 133 30161 6469 64461969
Dehydration 337.68 18.70 460 29834 216303 64252135
Malignant neoplasm progression 311.29 18.70 321 29973 112550 64355888
Neutropenia 300.75 18.70 459 29835 239165 64229273
Paronychia 291.25 18.70 111 30183 6381 64462057
Radiation skin injury 289.61 18.70 76 30218 1254 64467184
Infusion related reaction 275.75 18.70 362 29932 164105 64304333
Diarrhoea 246.56 18.70 820 29474 721884 63746554
Anaphylactic reaction 219.99 18.70 212 30082 68452 64399986
Rash 209.17 18.70 577 29717 457972 64010466
Stomatitis 201.98 18.70 253 30041 109352 64359086
Drug ineffective 177.68 18.70 87 30207 840160 63628278
Chills 144.42 18.70 243 30051 137021 64331417
Palmar-plantar erythrodysaesthesia syndrome 140.49 18.70 113 30181 28706 64439732
Arthralgia 132.49 18.70 24 30270 442236 64026202
Dysphagia 124.36 18.70 198 30096 106614 64361824
Dermatitis 105.97 18.70 79 30215 17950 64450488
Vomiting 104.86 18.70 523 29771 550594 63917844
Pharyngeal inflammation 101.29 18.70 31 30263 908 64467530
Skin fissures 101.00 18.70 62 30232 10244 64458194
Disease progression 100.54 18.70 212 30082 141468 64326970
Pulmonary embolism 99.26 18.70 215 30079 146141 64322297
Decreased appetite 98.47 18.70 323 29971 280966 64187472
Drug interaction 93.71 18.70 27 30267 362056 64106382
Thrombocytopenia 86.51 18.70 266 30028 223535 64244903
Skin reaction 83.69 18.70 59 30235 12293 64456145
Serous retinal detachment 83.69 18.70 25 30269 673 64467765
Leukopenia 83.12 18.70 161 30133 101081 64367357
Febrile neutropenia 82.97 18.70 234 30060 187423 64281015
Pyrexia 82.49 18.70 495 29799 558149 63910289
Hypocalcaemia 81 18.70 99 30195 41654 64426784
Metastases to lung 78.97 18.70 62 30232 15202 64453236
Nausea 78.73 18.70 633 29661 785167 63683271
Joint swelling 78.36 18.70 6 30288 215376 64253062
Neuropathy peripheral 77.77 18.70 171 30123 117354 64351084
Hypotension 77.61 18.70 369 29925 380605 64087833
Interstitial lung disease 77.29 18.70 153 30141 97579 64370859
Acne 77.13 18.70 73 30221 23008 64445430
Rash pustular 73.51 18.70 50 30244 9835 64458603
Peripheral swelling 72.88 18.70 7 30287 209146 64259292
Fall 72.56 18.70 54 30240 416772 64051666
Condition aggravated 71.88 18.70 43 30251 372383 64096055
Nasopharyngitis 69.83 18.70 6 30288 196067 64272371
Ileus 68.04 18.70 68 30226 22898 64445540
Hypokalaemia 67.09 18.70 165 30129 121738 64346700
Conjunctivitis 65.40 18.70 63 30231 20291 64448147
Pain in extremity 64.31 18.70 31 30263 303054 64165384
Neutrophil count decreased 63.63 18.70 123 30171 77073 64391365
Weight increased 60.78 18.70 13 30281 213335 64255103
Headache 60.74 18.70 97 30197 529370 63939068
Product dose omission issue 59.45 18.70 10 30284 194737 64273701
Dry skin 58.33 18.70 94 30200 51067 64417371
Radiation mucositis 58.01 18.70 14 30280 161 64468277
Erythema 57.63 18.70 206 30088 186864 64281574
Flushing 54.93 18.70 117 30177 78531 64389907
Pulse absent 54.36 18.70 40 30254 8906 64459532
Tumour haemorrhage 53.09 18.70 28 30266 3465 64464973
Hypersensitivity 52.74 18.70 207 30087 196245 64272193
Device related infection 50.51 18.70 67 30227 30559 64437879
Drug abuse 50.14 18.70 3 30291 132371 64336067
Metastases to liver 50.08 18.70 59 30235 23882 64444556
Onycholysis 49.37 18.70 21 30273 1605 64466833
Abdominal discomfort 48.21 18.70 13 30281 182309 64286129
Toxicity to various agents 47.15 18.70 61 30233 363452 64104986
Dyspnoea 45.92 18.70 527 29767 718147 63750291
White blood cell count decreased 45.37 18.70 170 30124 157667 64310771
Haematotoxicity 43.48 18.70 41 30253 12855 64455583
Drug intolerance 43.37 18.70 17 30277 187975 64280463
Anaemia 43.22 18.70 315 29979 378365 64090073
Therapeutic product effect decreased 42.54 18.70 3 30291 115348 64353090
Neoplasm progression 42.30 18.70 72 30222 40892 64427546
Insomnia 42.29 18.70 20 30274 197816 64270622
Enteritis 41.88 18.70 39 30255 12038 64456400
Sepsis 41.03 18.70 215 30079 230126 64238312
Musculoskeletal stiffness 40.67 18.70 5 30289 123201 64345237
Gait disturbance 40.66 18.70 15 30279 172140 64296298
Gastrointestinal toxicity 39.76 18.70 27 30267 5295 64463143
Sinusitis 39.35 18.70 10 30284 145918 64322520
Contusion 39.19 18.70 4 30290 113961 64354477
Product use issue 37.94 18.70 12 30282 151703 64316735
Pain 37.43 18.70 134 30160 553377 63915061
Blood magnesium decreased 37.24 18.70 39 30255 13866 64454572
Blood pressure immeasurable 36.90 18.70 18 30276 1890 64466548
Oesophagitis 36.72 18.70 48 30246 21582 64446856
Contraindicated product administered 36.53 18.70 4 30290 107825 64360613
Proteus infection 36.35 18.70 17 30277 1626 64466812
Deep vein thrombosis 34.22 18.70 118 30176 105064 64363374
Oxygen saturation decreased 33.80 18.70 119 30175 107057 64361381
Clostridial infection 33.63 18.70 24 30270 5095 64463343
Influenza 33.55 18.70 5 30289 106526 64361912
Nail dystrophy 33.24 18.70 13 30281 800 64467638
Pneumonitis 32.96 18.70 73 30221 50292 64418146
Drug hypersensitivity 32.82 18.70 38 30256 237777 64230661
Anaphylactic shock 32.23 18.70 54 30240 30274 64438164
Subileus 31.93 18.70 23 30271 4954 64463484
Necrotising oesophagitis 31.67 18.70 12 30282 678 64467760
Pneumatosis intestinalis 30.91 18.70 23 30271 5206 64463232
Laryngeal oedema 30.70 18.70 26 30268 7087 64461351
Bronchospasm 30.59 18.70 44 30250 21638 64446800
Cerebral ischaemia 30.43 18.70 30 30264 9932 64458506
Trichomegaly 29.05 18.70 7 30287 80 64468358
Asthma 28.80 18.70 5 30289 95220 64373218
Embolism 28.71 18.70 32 30262 12203 64456235
Prothrombin level decreased 28.68 18.70 14 30280 1472 64466966
Nail disorder 28.28 18.70 27 30267 8597 64459841
Neurotoxicity 28.07 18.70 48 30246 27356 64441082
Hepatic enzyme increased 27.97 18.70 13 30281 129930 64338508
Aspiration 27.93 18.70 37 30257 16848 64451590
Small intestinal obstruction 27.80 18.70 44 30250 23529 64444909
Bone marrow failure 27.51 18.70 66 30228 47886 64420552
Periorbital disorder 27.40 18.70 6 30288 43 64468395
Discomfort 27.39 18.70 3 30291 80875 64387563
Pneumonia aspiration 27.21 18.70 75 30219 59196 64409242
K-ras gene mutation 27.17 18.70 6 30288 45 64468393
Hyperbilirubinaemia 26.99 18.70 41 30253 21164 64447274
Staphylococcal infection 26.17 18.70 67 30227 50611 64417827
Blood pressure decreased 25.71 18.70 94 30200 86105 64382333
Intestinal obstruction 25.34 18.70 54 30240 36232 64432206
Anxiety 25.23 18.70 35 30259 202614 64265824
Hospitalisation 24.94 18.70 3 30291 75204 64393234
Monocytopenia 24.90 18.70 7 30287 151 64468287
Venous thrombosis 24.86 18.70 22 30272 6359 64462079
Overdose 24.82 18.70 23 30271 159543 64308895
Bronchitis 24.80 18.70 10 30284 108733 64359705
Myelosuppression 24.75 18.70 42 30252 23788 64444650
Colorectal cancer metastatic 24.59 18.70 11 30283 949 64467489
Induration 24.33 18.70 13 30281 1651 64466787
Cardio-respiratory arrest 24.23 18.70 101 30193 98292 64370146
Balance disorder 24.11 18.70 5 30289 83921 64384517
Swelling 23.87 18.70 24 30270 160194 64308244
Cardiac failure congestive 23.87 18.70 16 30278 130564 64337874
Gastrooesophageal reflux disease 23.79 18.70 5 30289 83138 64385300
Abdominal pain 23.51 18.70 237 30057 312138 64156300
Treatment failure 23.18 18.70 13 30281 116803 64351635
Wound 23.16 18.70 4 30290 76473 64391965
Memory impairment 22.84 18.70 6 30288 85676 64382762
Multiple-drug resistance 22.55 18.70 21 30273 6481 64461957
Ileal perforation 22.10 18.70 10 30284 886 64467552
Arthritis 22.10 18.70 6 30288 83808 64384630
Depression 21.49 18.70 33 30261 183258 64285180
Respiratory distress 20.90 18.70 63 30231 52268 64416170
Wrong technique in product usage process 20.57 18.70 3 30291 64971 64403467
Glossodynia 20.45 18.70 3 30291 64693 64403745
Abdominal compartment syndrome 20.44 18.70 11 30283 1417 64467021
Tachycardia 20.32 18.70 130 30164 149449 64318989
Carcinoembryonic antigen increased 20.24 18.70 12 30282 1861 64466577
Haemolytic uraemic syndrome 20.08 18.70 16 30278 4005 64464433
Lymphopenia 20.05 18.70 40 30254 25617 64442821
Osteoarthritis 19.88 18.70 3 30291 63333 64405105
Intentional product use issue 19.82 18.70 10 30284 95354 64373084
Hypertrichosis 19.74 18.70 10 30284 1138 64467300
Stress cardiomyopathy 19.67 18.70 23 30271 9234 64459204
Hallucination 19.59 18.70 5 30289 72783 64395655
Hypovolaemic shock 19.35 18.70 24 30270 10242 64458196
Nail toxicity 19.31 18.70 7 30287 349 64468089
Myalgia 19.14 18.70 28 30266 158589 64309849
Pruritus 18.89 18.70 227 30067 312173 64156265
Granulocyte count decreased 18.75 18.70 10 30284 1266 64467172

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01FE01 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
EGFR (Epidermal Growth Factor Receptor) inhibitors
FDA MoA N0000020010 HER1 Antagonists
MeSH PA D000970 Antineoplastic Agents
MeSH PA D000074322 Antineoplastic Agents, Immunological
FDA EPC N0000175664 Epidermal Growth Factor Receptor Antagonist

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Squamous cell carcinoma of mouth indication 307502000
Rectal cancer with wild-type RAS indication 363351006 DOID:1993
Malignant tumor of colon indication 363406005 DOID:219
Squamous cell carcinoma of larynx indication 405822008
Squamous cell carcinoma of pharynx indication 408649007
Squamous cell carcinoma of nose indication 448930008




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Epidermal growth factor receptor Kinase ANTIBODY BINDING Kd 9.41 IUPHAR DRUG LABEL

External reference:

IDSource
D03455 KEGG_DRUG
4021419 VUID
N0000148833 NUI
4021419 VANDF
CHEMBL1201577 ChEMBL_ID
6882 IUPHAR_LIGAND_ID
7906 INN_ID
DB00002 DRUGBANK_ID
PQX0D8J21J UNII
14122979 PUBCHEM_CID
318341 RXNORM
17947 MMSL
48970 MMSL
d05101 MMSL
409400001 SNOMEDCT_US
409401002 SNOMEDCT_US
D000068818 MESH_DESCRIPTOR_UI
C0995188 UMLSCUI
008568 NDDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
ERBITUX HUMAN PRESCRIPTION DRUG LABEL 1 66733-948 SOLUTION 2 mg INTRAVENOUS BLA 29 sections
ERBITUX HUMAN PRESCRIPTION DRUG LABEL 1 66733-958 SOLUTION 2 mg INTRAVENOUS BLA 29 sections